Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research using unique medicinal chemistry to create a highly potent DNA alkylating agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology models have shown CT-262 to produce markedly better efficacy and safety results than current first-line therapies and highlight the potential to replace these compounds in a broad array of cancers.
Company Details
- Employees
- 4
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://cairntherapeutics.com/
Cairn Therapeutics Questions
Cairn Therapeutics's website is https://cairntherapeutics.com/
Cairn Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cairn-therapeutics
Cairn Therapeutics has
4 employees.
View email and phone details for 4
employees at Cairn Therapeutics.
Cairn Therapeutics's industry is
Biotechnology Research
Cairn Therapeutics's top competitors are
Mallinckrodt Pharmaceuticals,
Evotec,
Leal Therapeutics,
Blue Earth Therapeutics,
Evommune,
Belhaven Biopharma,
Tikkunlev Therapeutics,
Kreamedica Inc.,
Axonis Therapeutics,
Pathos.
Cairn Therapeutics's categories are Biotechnology Research
Cairn Therapeutics's founding year is 2016
